IDEXX Laboratories (IDXX) Getting Somewhat Positive Media Coverage, Report Shows
Media stories about IDEXX Laboratories (NASDAQ:IDXX) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. IDEXX Laboratories earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.916125638235 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Zacks: Analysts Expect IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $491.02 Million (americanbankingnews.com)
- Zacks: Analysts Expect IDEXX Laboratories, Inc. (IDXX) to Post $0.73 Earnings Per Share (americanbankingnews.com)
- IDEXX Laboratories to Present at J.P. Morgan Healthcare Conference (finance.yahoo.com)
- IDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : January 1, 2018 (finance.yahoo.com)
Shares of IDEXX Laboratories (NASDAQ IDXX) traded up $1.91 during mid-day trading on Thursday, hitting $163.96. 520,202 shares of the stock traded hands, compared to its average volume of 440,967. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. IDEXX Laboratories has a 52-week low of $115.30 and a 52-week high of $173.01. The firm has a market cap of $14,300.00, a price-to-earnings ratio of 53.23, a P/E/G ratio of 2.17 and a beta of 0.42.
Several research firms have recently weighed in on IDXX. Canaccord Genuity reissued a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a research note on Friday, October 6th. Aegis reissued a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target for the company in a research note on Tuesday, October 24th. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Finally, BidaskClub cut shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, December 16th. Three equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $173.67.
In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $153.75, for a total transaction of $2,767,500.00. Following the sale, the chief executive officer now directly owns 1,064,573 shares in the company, valued at approximately $163,678,098.75. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Chairman Jonathan W. Ayers sold 54,000 shares of the stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the sale, the chairman now owns 1,064,573 shares in the company, valued at $161,091,186.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 110,000 shares of company stock worth $16,686,200. Company insiders own 2.77% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “IDEXX Laboratories (IDXX) Getting Somewhat Positive Media Coverage, Report Shows” was reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.mareainformativa.com/2018/01/04/idexx-laboratories-idxx-getting-somewhat-positive-media-coverage-report-shows.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.